Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical ...
A new small molecule drug helps to bind the naturally occurring cellular chaperone cyclophilin A (CYPA) to the active state of the cancer-causing mutant KRAS G12C, disrupting oncogenic signaling and ...
Scientists in the U.K. have discovered how poxviruses such as the monkeypox virus (MPXV) and variola viruses evade host cell defenses by exploiting a protein, cyclophilin A (CypA), that puts the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results